Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas - A Pilot Study

Hiroyuki Shiba, Koji Takeuchi, Ryo Hiramatsu, Motomasa Furuse, Naosuke Nonoguchi, Shinji Kawabata, Toshihiko Kuroiwa, Natsuko Kondo, Yoshinori Sakurai, Minoru Suzuki, Koji Ono, Shiro Oue, Eiichi Ishikawa, Hiroyuki Michiue, Shin Ichi Miyatake

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recurrent malignant gliomas (RMGs) are difficult to control, and no standard protocol has been established for their treatment. At our institute, we have often treated RMGs by tumor-selective particle radiation called boron neutron capture therapy (BNCT). However, despite the cell-selectivity of BNCT, brain radiation necrosis (BRN) may develop and cause severe neurological complications and sometimes death. This is partly due to the full-dose X-ray treatments usually given earlier in the treatment course. To overcome BRN following BNCT, recent studies have used bevacizumab (BV). We herein used extended BV treatment beginning just after BNCT to confer protection against or ameliorate BRN, and evaluated; the feasibility, efficacy, and BRN control of this combination treatment. Seven patients with RMGs (grade 3 and 4 cases) were treated with BNCT between June 2013 and May 2014, followed by successive BV treatments. They were followed-up to December 2017. Median overall survival (OS) and progression-free survival (PFS) after combination treatment were 15.1 and 5.4 months, respectively. In one case, uncontrollable brain edema occurred and ultimately led to death after BV was interrupted due to meningitis. In two other cases, symptomatic aggravation of BRN occurred after interruption of BV treatment. No BRN was observed during the observation period in the other cases. Common terminology criteria for adverse events grade 2 and 3 proteinuria occurred in two cases and necessitated the interruption of BV treatments. Boron neutron capture therapy followed by BV treatments well-prevented or well-controlled BRN with prolonged OS and acceptable incidence of adverse events in our patients with RMG.

Original languageEnglish
Pages (from-to)487-494
Number of pages8
JournalNeurologia Medico-Chirurgica
Volume58
Issue number12
DOIs
Publication statusPublished - Dec 15 2018

Fingerprint

Boron Neutron Capture Therapy
Glioma
Radiation
Necrosis
Brain
Therapeutics
Bevacizumab
Survival
Brain Edema
Proteinuria
Meningitis
Terminology
Disease-Free Survival

Keywords

  • bevacizumab
  • boron neutron capture therapy
  • brain radiation necrosis
  • recurrent malignant glioma

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas - A Pilot Study. / Shiba, Hiroyuki; Takeuchi, Koji; Hiramatsu, Ryo; Furuse, Motomasa; Nonoguchi, Naosuke; Kawabata, Shinji; Kuroiwa, Toshihiko; Kondo, Natsuko; Sakurai, Yoshinori; Suzuki, Minoru; Ono, Koji; Oue, Shiro; Ishikawa, Eiichi; Michiue, Hiroyuki; Miyatake, Shin Ichi.

In: Neurologia Medico-Chirurgica, Vol. 58, No. 12, 15.12.2018, p. 487-494.

Research output: Contribution to journalArticle

Shiba, H, Takeuchi, K, Hiramatsu, R, Furuse, M, Nonoguchi, N, Kawabata, S, Kuroiwa, T, Kondo, N, Sakurai, Y, Suzuki, M, Ono, K, Oue, S, Ishikawa, E, Michiue, H & Miyatake, SI 2018, 'Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas - A Pilot Study', Neurologia Medico-Chirurgica, vol. 58, no. 12, pp. 487-494. https://doi.org/10.2176/nmc.oa.2018-0111
Shiba, Hiroyuki ; Takeuchi, Koji ; Hiramatsu, Ryo ; Furuse, Motomasa ; Nonoguchi, Naosuke ; Kawabata, Shinji ; Kuroiwa, Toshihiko ; Kondo, Natsuko ; Sakurai, Yoshinori ; Suzuki, Minoru ; Ono, Koji ; Oue, Shiro ; Ishikawa, Eiichi ; Michiue, Hiroyuki ; Miyatake, Shin Ichi. / Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas - A Pilot Study. In: Neurologia Medico-Chirurgica. 2018 ; Vol. 58, No. 12. pp. 487-494.
@article{590e8c26567244f084ae2f2846fdc43d,
title = "Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas - A Pilot Study",
abstract = "Recurrent malignant gliomas (RMGs) are difficult to control, and no standard protocol has been established for their treatment. At our institute, we have often treated RMGs by tumor-selective particle radiation called boron neutron capture therapy (BNCT). However, despite the cell-selectivity of BNCT, brain radiation necrosis (BRN) may develop and cause severe neurological complications and sometimes death. This is partly due to the full-dose X-ray treatments usually given earlier in the treatment course. To overcome BRN following BNCT, recent studies have used bevacizumab (BV). We herein used extended BV treatment beginning just after BNCT to confer protection against or ameliorate BRN, and evaluated; the feasibility, efficacy, and BRN control of this combination treatment. Seven patients with RMGs (grade 3 and 4 cases) were treated with BNCT between June 2013 and May 2014, followed by successive BV treatments. They were followed-up to December 2017. Median overall survival (OS) and progression-free survival (PFS) after combination treatment were 15.1 and 5.4 months, respectively. In one case, uncontrollable brain edema occurred and ultimately led to death after BV was interrupted due to meningitis. In two other cases, symptomatic aggravation of BRN occurred after interruption of BV treatment. No BRN was observed during the observation period in the other cases. Common terminology criteria for adverse events grade 2 and 3 proteinuria occurred in two cases and necessitated the interruption of BV treatments. Boron neutron capture therapy followed by BV treatments well-prevented or well-controlled BRN with prolonged OS and acceptable incidence of adverse events in our patients with RMG.",
keywords = "bevacizumab, boron neutron capture therapy, brain radiation necrosis, recurrent malignant glioma",
author = "Hiroyuki Shiba and Koji Takeuchi and Ryo Hiramatsu and Motomasa Furuse and Naosuke Nonoguchi and Shinji Kawabata and Toshihiko Kuroiwa and Natsuko Kondo and Yoshinori Sakurai and Minoru Suzuki and Koji Ono and Shiro Oue and Eiichi Ishikawa and Hiroyuki Michiue and Miyatake, {Shin Ichi}",
year = "2018",
month = "12",
day = "15",
doi = "10.2176/nmc.oa.2018-0111",
language = "English",
volume = "58",
pages = "487--494",
journal = "Neurologia Medico-Chirurgica",
issn = "0470-8105",
publisher = "Japan Neurosurgical Society",
number = "12",

}

TY - JOUR

T1 - Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas - A Pilot Study

AU - Shiba, Hiroyuki

AU - Takeuchi, Koji

AU - Hiramatsu, Ryo

AU - Furuse, Motomasa

AU - Nonoguchi, Naosuke

AU - Kawabata, Shinji

AU - Kuroiwa, Toshihiko

AU - Kondo, Natsuko

AU - Sakurai, Yoshinori

AU - Suzuki, Minoru

AU - Ono, Koji

AU - Oue, Shiro

AU - Ishikawa, Eiichi

AU - Michiue, Hiroyuki

AU - Miyatake, Shin Ichi

PY - 2018/12/15

Y1 - 2018/12/15

N2 - Recurrent malignant gliomas (RMGs) are difficult to control, and no standard protocol has been established for their treatment. At our institute, we have often treated RMGs by tumor-selective particle radiation called boron neutron capture therapy (BNCT). However, despite the cell-selectivity of BNCT, brain radiation necrosis (BRN) may develop and cause severe neurological complications and sometimes death. This is partly due to the full-dose X-ray treatments usually given earlier in the treatment course. To overcome BRN following BNCT, recent studies have used bevacizumab (BV). We herein used extended BV treatment beginning just after BNCT to confer protection against or ameliorate BRN, and evaluated; the feasibility, efficacy, and BRN control of this combination treatment. Seven patients with RMGs (grade 3 and 4 cases) were treated with BNCT between June 2013 and May 2014, followed by successive BV treatments. They were followed-up to December 2017. Median overall survival (OS) and progression-free survival (PFS) after combination treatment were 15.1 and 5.4 months, respectively. In one case, uncontrollable brain edema occurred and ultimately led to death after BV was interrupted due to meningitis. In two other cases, symptomatic aggravation of BRN occurred after interruption of BV treatment. No BRN was observed during the observation period in the other cases. Common terminology criteria for adverse events grade 2 and 3 proteinuria occurred in two cases and necessitated the interruption of BV treatments. Boron neutron capture therapy followed by BV treatments well-prevented or well-controlled BRN with prolonged OS and acceptable incidence of adverse events in our patients with RMG.

AB - Recurrent malignant gliomas (RMGs) are difficult to control, and no standard protocol has been established for their treatment. At our institute, we have often treated RMGs by tumor-selective particle radiation called boron neutron capture therapy (BNCT). However, despite the cell-selectivity of BNCT, brain radiation necrosis (BRN) may develop and cause severe neurological complications and sometimes death. This is partly due to the full-dose X-ray treatments usually given earlier in the treatment course. To overcome BRN following BNCT, recent studies have used bevacizumab (BV). We herein used extended BV treatment beginning just after BNCT to confer protection against or ameliorate BRN, and evaluated; the feasibility, efficacy, and BRN control of this combination treatment. Seven patients with RMGs (grade 3 and 4 cases) were treated with BNCT between June 2013 and May 2014, followed by successive BV treatments. They were followed-up to December 2017. Median overall survival (OS) and progression-free survival (PFS) after combination treatment were 15.1 and 5.4 months, respectively. In one case, uncontrollable brain edema occurred and ultimately led to death after BV was interrupted due to meningitis. In two other cases, symptomatic aggravation of BRN occurred after interruption of BV treatment. No BRN was observed during the observation period in the other cases. Common terminology criteria for adverse events grade 2 and 3 proteinuria occurred in two cases and necessitated the interruption of BV treatments. Boron neutron capture therapy followed by BV treatments well-prevented or well-controlled BRN with prolonged OS and acceptable incidence of adverse events in our patients with RMG.

KW - bevacizumab

KW - boron neutron capture therapy

KW - brain radiation necrosis

KW - recurrent malignant glioma

UR - http://www.scopus.com/inward/record.url?scp=85058735005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058735005&partnerID=8YFLogxK

U2 - 10.2176/nmc.oa.2018-0111

DO - 10.2176/nmc.oa.2018-0111

M3 - Article

C2 - 30464150

AN - SCOPUS:85058735005

VL - 58

SP - 487

EP - 494

JO - Neurologia Medico-Chirurgica

JF - Neurologia Medico-Chirurgica

SN - 0470-8105

IS - 12

ER -